Galanin-acetylcholine interactions: Relevance to memory and Alzheimer's disease

Jacqueline Crawley

doi:10.1016/0024-3205(96)00093-8

Galanin-acetylcholine interactions: Relevance to memory and Alzheimer's disease

Jacqueline Crawley

Research output: Contribution to journal › Article

113 Scopus citations

Abstract

The neuropeptide, galanin, and its receptors are localized in the cholinergic basal forebrain and its projection areas in mammalian brain. Centrally administered galanin inhibits acetylcholine release in the rat ventral hippocampus, and produces deficits in learning and memory tasks. In Alzheimer's disease, galanin is overexpressed in terminals innervating the nucleus basalis of Meynert cell bodies. Selective galanin receptor antagonists provide a novel approach for increasing cholinergic function, as a potential adjunct to the clinical treatment of dementias.

Original language	English (US)
Pages (from-to)	2185-2199
Number of pages	15
Journal	Life Sciences
Volume	58
Issue number	24
DOIs	https://doi.org/10.1016/0024-3205(96)00093-8
State	Published - May 10 1996
Externally published	Yes

Keywords

Acetylcholine
Alzheimer's disease
Galanin
Learning and memory
Neuropeptide
Neurotransmitter release

ASJC Scopus subject areas

Pharmacology

Access to Document

10.1016/0024-3205(96)00093-8

Fingerprint Dive into the research topics of 'Galanin-acetylcholine interactions: Relevance to memory and Alzheimer's disease'. Together they form a unique fingerprint.

Cite this

Crawley, J. (1996). Galanin-acetylcholine interactions: Relevance to memory and Alzheimer's disease. Life Sciences, 58(24), 2185-2199. https://doi.org/10.1016/0024-3205(96)00093-8

@article{e8a66d3b80af4cc3b60a253621a1ea09,

title = "Galanin-acetylcholine interactions: Relevance to memory and Alzheimer's disease",

abstract = "The neuropeptide, galanin, and its receptors are localized in the cholinergic basal forebrain and its projection areas in mammalian brain. Centrally administered galanin inhibits acetylcholine release in the rat ventral hippocampus, and produces deficits in learning and memory tasks. In Alzheimer's disease, galanin is overexpressed in terminals innervating the nucleus basalis of Meynert cell bodies. Selective galanin receptor antagonists provide a novel approach for increasing cholinergic function, as a potential adjunct to the clinical treatment of dementias.",

keywords = "Acetylcholine, Alzheimer's disease, Galanin, Learning and memory, Neuropeptide, Neurotransmitter release",

author = "Jacqueline Crawley",

year = "1996",

month = may,

day = "10",

doi = "10.1016/0024-3205(96)00093-8",

language = "English (US)",

volume = "58",

pages = "2185--2199",

journal = "Life Sciences",

issn = "0024-3205",

publisher = "Elsevier Inc.",

number = "24",

}

TY - JOUR

T1 - Galanin-acetylcholine interactions

T2 - Relevance to memory and Alzheimer's disease

AU - Crawley, Jacqueline

PY - 1996/5/10

Y1 - 1996/5/10

N2 - The neuropeptide, galanin, and its receptors are localized in the cholinergic basal forebrain and its projection areas in mammalian brain. Centrally administered galanin inhibits acetylcholine release in the rat ventral hippocampus, and produces deficits in learning and memory tasks. In Alzheimer's disease, galanin is overexpressed in terminals innervating the nucleus basalis of Meynert cell bodies. Selective galanin receptor antagonists provide a novel approach for increasing cholinergic function, as a potential adjunct to the clinical treatment of dementias.

AB - The neuropeptide, galanin, and its receptors are localized in the cholinergic basal forebrain and its projection areas in mammalian brain. Centrally administered galanin inhibits acetylcholine release in the rat ventral hippocampus, and produces deficits in learning and memory tasks. In Alzheimer's disease, galanin is overexpressed in terminals innervating the nucleus basalis of Meynert cell bodies. Selective galanin receptor antagonists provide a novel approach for increasing cholinergic function, as a potential adjunct to the clinical treatment of dementias.

KW - Acetylcholine

KW - Alzheimer's disease

KW - Galanin

KW - Learning and memory

KW - Neuropeptide

KW - Neurotransmitter release

UR - http://www.scopus.com/inward/record.url?scp=0029689910&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029689910&partnerID=8YFLogxK

U2 - 10.1016/0024-3205(96)00093-8

DO - 10.1016/0024-3205(96)00093-8

M3 - Article

C2 - 8649205

AN - SCOPUS:0029689910

VL - 58

SP - 2185

EP - 2199

JO - Life Sciences

JF - Life Sciences

SN - 0024-3205

IS - 24

ER -